[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Arguments for and against boosters", "description": "FDA panel reports, against boosters for all\n\nhttps://www.washingtonpost.com/health/2021/09/17/covid-booster-shots-fda-recommendation/\n\nFood and Drug Administration\n\nBoosters for all (16:2)\n\nUnanimously, a booster shot of Pfizer-BioNTech (18:0)\n\nSix months (minimum) after vaccination\n\nPeople 65 + and anyone at risk for severe illness\n\nFinal decision, may include occupational exposure\n\nCenters for Disease Control and Prevention to advise next week\n\nAdministration wanted it for all 16 +\n\n81 million had Moderna or Johnson & Johnson\n\nAgainst boosters for all\n\nhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02046-8/fulltext\n\nEnhancing immunity in vaccinated people is appealing\n\nShould be evidence-based\n\nConsider the benefits and risks for individuals and society\n\nCOVID-19 vaccines continue to be effective against severe disease, including that caused by the delta variant\n\nCDC, Sara Oliver\n\nThrough July, adults 75 and older were 88%\nprotected against hospitalization\n\nDecisions about boosting are informed by reliable science more than by politics. \n\nObservational studies\n\nPfizer was a co-sponsor of the study\n\nCurrent vaccine supplies could save more lives if used in previously unvaccinated populations\n\nIn favour for the immunocompromised, but ? different vaccine\n\nBoosting might ultimately be needed in all\n\nE.g. waning immunity or because variants expressing new antigens\n\nBoosters may have immune-mediated side-effects such as myocarditis (more common after 2nd dose)\n\nImplications for vaccine acceptance\n\nFurther reasoning\n\nEven if humoral immunity appears to wane\n\nInitial vaccine type still elicit humoral immune responses against delta\n\n (rather than variant-specific antigens)\n\nIndicates that delta has not evolved to escape the memory immune responses\n\nThere is an opportunity now to study variant-based boosters\n\nRobust booster responses might be achievable at lower doses\n\nFor boosters for all\n\nIsrael\n\nProtection had waned\n\nBooster campaign started end of July\n\nSharon Alroy-Preis, director of public health, Israel\u2019s Ministry of Health\n\nThousands of cases, doubling every 10 days\n\nIf we had not started boosters at the end of July, we would have come to the capacity of Israeli hospitalization capabilities \u2014 and gone beyond it\n\nProtection of BNT162b2 Vaccine Booster against Covid-19 in Israel\n\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa2114255\n\nHTTPS://WWW.NATURE.COM/ARTICLES/D41586-021-02516-4\n\n30th July to 31st August 2021\n\nAt least 5 months earlier\n\nn = 1,137,804 over 60s\n\nConfirmed infections, 4,439\n\nSevere illness, 294\n\nBooster group\n\nDoubly vaccinated\n\nRate of confirmed Covid-19\n\nRate of severe illness\n\nAt least 12 days after booster dose\n\nNonbooster group\n\nDoubly vaccinated\n\nRate of confirmed Covid-19\n\nRate of severe illness\n\nResults, rate of confirmed infections\n\nLower in the booster group\n\nHigher in the nonbooster group\n\nBy a factor of 11.3\n\nResults, rate of severe illness\n\nRate of confirmed infection\n\nLower in the booster group\n\nHigher in the nonbooster group\n\nBy a factor of 19.5\n\nhttps://www.fda.gov/media/152205/download\n\nHolding true down to 40 so far", "link": "https://www.youtube.com/watch?v=hVtX7tY1B0U", "date_published": "2021-09-19 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]